A catalyst-rich biotech may be poised to resume its recovery. Use options to take advantage

Buy the REGN June $700/$850 bull call spread, target entry around $78–79 debit; max gain ~$71–72 and max loss limited to the premium paid. REGN trades near $765 after a ~60% run over seven months but remains well below 2025 highs >$1,100; catalysts include earnings on April 29, an early-June shareholder meeting, and potential oncology/obesity approvals. FY2026 revenue est $15.7B (+9.5% YoY) with FCF yield >6% and valuation ~16–17x forward earnings, while Eylea erosion vs Roche's Vabysmo is an acknowledged headwind—supporting a defined‑risk bullish trade.

Analysis

Regeneron's near-term re-rating will be driven more by optics around optionality than by a single binary outcome; that makes calendar placement and volatility management the primary trade decisions. A catalyst-packed cadence over the next 6–12 weeks raises event-driven IV, so positioning that benefits from a directional recovery while capping vega exposure is attractive.

Second-order beneficiaries include specialty contract manufacturers and select CROs that carry oncology and biologics programs—positive read-throughs on program progression can concentrate revenue upside into a narrow supplier base and produce outsized moves in smaller-cap vendors. Conversely, legacy retinal incumbents and payers could accelerate mix shifts if a new entrant meaningfully regains share, creating a two-way flow into both innovators and suppliers.

Tail risks are dominated by earnings/clinical headline fatigue and accelerated biosimilar adoption; both can produce abrupt delta moves and IV collapses. Manage these by trading defined-risk option structures, staggering entries relative to earnings/meeting windows, and sizing position gamma so a 5–10% spot move before you can rebalance won't force liquidation.

Key Decisions for Investors

• Buy a defined-width vertical call spread on REGN expiring in ~6–8 weeks (debit entry only if cost <=55% of width). Rationale: participate in directional recovery while limiting vega exposure. Size to cap P&L at single-digit percent of equity book; target 1.2–1.6x return if short strike is touched by expiration; stop-loss: close at 50% of premium paid.
• Delay full allocation until after the upcoming earnings print; if IV spikes pre-earnings, sell a small portion of calendar call premium (monthly calls) to convert outright long exposure into a financed directional position. This converts theta headwind into a controlled carry trade while keeping upside.
• Pair hedge: initiate a short-call spread on NVO (near-term) sized ~30–50% of REGN notional to neutralize sector obesity headline risk. If competitor headlines are adverse, the pair reduces gross exposure to GLP-1 macro moves while keeping biotech-specific upside active.
• Hedge tail: buy out-of-the-money puts with longer-dated expiries (3–6 months) sized to protect 20–30% of notional against a >20% drawdown tied to biosimilar acceleration or safety shock. Cost is insurance—accept single-digit hit to max return in exchange for convex downside protection.
• Long-term directional: accumulate LEAP call positions on weakness after any IV crush (post-event) to capture multi-year optionality from late-stage programs. Use a staggered buy schedule over the next 12 months and trim into any >30% rally to lock in carry for pipeline optionality.